Literature DB >> 30635721

Fundus autofluorescence and ellipsoid zone (EZ) line width can be an outcome measurement in RHO-associated autosomal dominant retinitis pigmentosa.

Vitor K L Takahashi1,2,3, Júlia T Takiuti1,2,4, Jose R L Carvalho-Jr1,2,3,5, Christine L Xu1,2, Jimmy K Duong6, Vinit B Mahajan7,8, Stephen H Tsang9,10,11,12.   

Abstract

PURPOSE: To evaluate the progression of retinitis pigmentosa (RP) due to mutations in rhodopsin (RHO) by measuring the short-wavelength autofluorescence (SW-AF) increased autofluorescence ring and ellipsoid zone (EZ)-line width.
METHODS: Fundus autofluorescence (FAF) and spectral domain optical coherence tomography (SD-OCT) images were obtained from 10 patients with autosomal dominant RP due to mutations in the RHO gene. Measurements of ring area on FAF images, as well as the EZ line width on SD-OCT images and horizontal, vertical diameter, were performed by two independent masked graders.
RESULTS: The ring area decreased by a rate of 0.6 ± 0.2 mm2 per year. We observed that the EZ line width decreased by an average of 152 ± 37 μm per year, while the horizontal and vertical diameters decreased by 106 ± 35 μm and 125 ± 29 μm per year, respectively. Progression rates were similar between eyes.
CONCLUSIONS: We observed SW-AF ring constriction and a progressive loss of EZ line width over time.

Entities:  

Keywords:  Autosomal dominant; Disease progression; RHO; Retinitis pigmentosa

Mesh:

Substances:

Year:  2019        PMID: 30635721     DOI: 10.1007/s00417-018-04234-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  10 in total

1.  Management of Retinitis Pigmentosa via Platelet-Rich Plasma or Combination with Electromagnetic Stimulation: Retrospective Analysis of 1-Year Results.

Authors:  Umut Arslan; Emin Özmert
Journal:  Adv Ther       Date:  2020-04-18       Impact factor: 3.845

2.  Association of retinal biomarkers and choroidal vascularity index on optical coherence tomography using binarization method in retinitis pigmentosa.

Authors:  Ebru N Cetin; Osman Parca; Hasan Samed Akkaya; Gökhan Pekel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-12       Impact factor: 3.117

3.  Clinical trial design for neuroprotection in RHO autosomal dominant retinitis pigmentosa; outcome measure considerations.

Authors:  Benjamin Otte; Chris Andrews; Gabrielle Lacy; Kari Branham; David C Musch; Kanishka T Jayasundera
Journal:  Ophthalmic Genet       Date:  2021-01-06       Impact factor: 1.803

Review 4.  Optical coherence tomography in the evaluation of retinitis pigmentosa.

Authors:  Jin Kyun Oh; Yan Nuzbrokh; Jose Ronaldo Lima de Carvalho; Joseph Ryu; Stephen H Tsang
Journal:  Ophthalmic Genet       Date:  2020-06-19       Impact factor: 1.274

5.  Rod function deficit in retained photoreceptors of patients with class B Rhodopsin mutations.

Authors:  Artur V Cideciyan; Samuel G Jacobson; Alejandro J Roman; Alexander Sumaroka; Vivian Wu; Jason Charng; Brianna Lisi; Malgorzata Swider; Gustavo D Aguirre; William A Beltran
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

6.  Novel mutations in the 3-box motif of the BACK domain of KLHL7 associated with nonsyndromic autosomal dominant retinitis pigmentosa.

Authors:  Jin Kyun Oh; Jose Ronaldo Lima de Carvalho; Young Joo Sun; Sara Ragi; Jing Yang; Sarah R Levi; Joseph Ryu; Alexander G Bassuk; Vinit B Mahajan; Stephen H Tsang
Journal:  Orphanet J Rare Dis       Date:  2019-12-19       Impact factor: 4.123

7.  Stationary and Progressive Phenotypes Caused by the p.G90D Mutation in Rhodopsin Gene.

Authors:  Nina Kobal; Tjaša Krašovec; Maja Šuštar; Marija Volk; Borut Peterlin; Marko Hawlina; Ana Fakin
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

8.  Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results.

Authors:  Emin Özmert; Umut Arslan
Journal:  Stem Cell Res Ther       Date:  2020-08-12       Impact factor: 6.832

9.  Autosomal Dominant Retinitis Pigmentosa Due to Class B Rhodopsin Mutations: An Objective Outcome for Future Treatment Trials.

Authors:  Alexander Sumaroka; Artur V Cideciyan; Jason Charng; Vivian Wu; Christian A Powers; Bhavya S Iyer; Brianna Lisi; Malgorzata Swider; Samuel G Jacobson
Journal:  Int J Mol Sci       Date:  2019-10-27       Impact factor: 5.923

Review 10.  Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations.

Authors:  Mays Talib; Camiel J F Boon
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2020 May-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.